Weeldreyer NR, De Guzman JC, Paterson C, Allen JD, Gaesser GA, Angadi SS
Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial
KEY FACTS -MASH is on the rise due to rising levels of obesity and T2DM
Patients injected exenatide twice daily for years, but researchers still wanted a once-weekly option-setting the stage for semaglutide and tirzepatide
Adults with a BMI 30, or 27 with conditions like PCOS, insulin resistance, or prediabetes Those who dont qualify foror cant affordbrand-name GLP-1s Patients seeking medically managed weight loss with ongoing support Anyone committed to sustainable, health-focused fat loss How to get started
Additionally, Ozempic enhances glucose-dependent insulin secretion and suppresses inappropriate glucagon release, improving glycaemic control in people with type 2 diabetes